Business: CareDx, Inc. is a commercial stage company that develops, markets and delivers a diagnostics surveillance solution for heart transplant recipients to help clinicians make personalized treatment decisions throughout a patient’s lifetime. Its commercialized testing solution, the AlloMap heart transplant molecular test, or AlloMap, is a blood-based tool used to monitor heart transplant recipients for acute cellular rejection. CareDx is seeking to apply its expertise in heart transplantation towards the development of additional solutions for organ transplant recipients, including recipients of heart and kidney transplants.